Coherus Oncology, Inc. (CHRS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Coherus Oncology, Inc. (CHRS) closed at USD 1.05 on 2026-10-14, a change of -39.7 % over the past year, with a market capitalization of USD 165.32M.

Coherus Oncology, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Coherus Oncology, Inc. key figures

Previous close

USD 1.05 (2026-10-14)

1-year change

-39.7 %

Market cap

USD 165.32M

Enterprise value

USD 114.19M

P/E ratio (trailing)

-0.86

P/E ratio (forward)

-1.70

EPS (trailing)

-1.25

EPS (forward)

-0.63

PEG ratio

n/a

Price to book

2.72

Revenue growth

39.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

17.72

Employees

144

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Coherus Oncology, Inc.

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Coherus Oncology, Inc. and compare it with other stocks.